Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out?

Company Performance - Arcutis Biotherapeutics, Inc. (ARQT) has seen a significant stock increase of 40.8% over the past month, reaching a new 52-week high of $28.96 [1] - The stock has gained 100.2% since the beginning of the year, outperforming the Zacks Medical sector's 4.8% and the Zacks Medical - Biomedical and Genetics industry's 15.8% returns [1] Earnings and Revenue Expectations - The company has a strong record of positive earnings surprises, beating the Zacks Consensus Estimate in each of the last four quarters, with the latest EPS reported at $0.06 against a consensus estimate of -$0.1 [2] - For the current fiscal year, Arcutis is expected to post earnings of -$0.24 per share on revenues of $360.24 million, reflecting a 79.31% change in EPS and an 83.29% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.41 per share on revenues of $470.02 million, indicating a year-over-year change of 273.61% in EPS and 30.47% in revenues [3] Valuation Metrics - The company has a Value Score of D, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [6] - Arcutis currently holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend [7][8] Industry Comparison - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 33% of all industries, providing favorable conditions for both Arcutis and its peer, Pharming Group N.V. [11]